Monique M. C Steijaert

Partially T-cell-depleted allogeneic stem-cell transplantation for first-line treatment of multiple myeloma: a prospective evaluation of patients treated in the phase III study HOVON 24 MM.

P. Sonneveld, B. van der Holt, M. V. van Oers, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high‐dose chemotherapy in patients with multiple myeloma

P. Sonneveld, B. van der Holt, G. Verhoef, 2007, British journal of haematology.

Overall and event-free survival are not improved by the use of myeloablative therapy following intensified chemotherapy in previously untreated patients with multiple myeloma: a prospective randomized phase 3 study.

J. Baars, P. Sonneveld, E. Vellenga, 2002, Blood.

CHOP compared with CHOP plus granulocyte colony-stimulating factor in elderly patients with aggressive non-Hodgkin's lymphoma.

P. Sonneveld, B. van der Holt, G. Ossenkoppele, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Self‐reported quality of life in elderly patients with aggressive non‐Hodgkin's lymphoma treated with CHOP chemotherapy

P. Sonneveld, J. Doorduijn, C. U. Uyl‐de Groot, 2005, European journal of haematology.

Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: a randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults.

P. Sonneveld, E. van den Berg, B. van der Holt, 2004, Leukemia research.

Intensified CHOP with Rituximab for Intermediate or High-Risk Non-Hodgkin’s Lymphoma: Interim Analysis of a Randomized Phase III Trial in Elderly Patients by the Dutch HOVON and Nordic Lymphoma Groups.

H. Holte, P. Sonneveld, M. Eriksson, 2005 .

Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.

P. Sonneveld, B. van der Holt, H. Kluin-Nelemans, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomized multicenter comparison of CD34(+)-selected progenitor cells from blood vs from bone marrow in recipients of HLA-identical allogeneic transplants for hematological malignancies.

M. Höglund, B. van der Holt, B. Löwenberg, 2003, Experimental hematology.

Phase III Trial of 2-Weekly CHOP with Rituximab for Aggressive B-Cell Non-Hodgkin’s Lymphoma in Elderly Patients.

H. Holte, P. Sonneveld, M. Eriksson, 2006 .